Casper Steenholdt

Casper Steenholdt

Auto-generated profile, based on publicly available information

Casper Steenholdt

Department of Gastroenterology, Herlev Hospital, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2011 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CSC. Steenholdt
C. Steenholdt
MSM. Svenson
M. Svenson
KBK. Bendtzen
K. Bendtzen
OTO. Ø. Thomsen
O. Ø. Thomsen
JBJ. Brynskov
J. Brynskov
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth

1 August 2013 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
CSCasper Steenholdt
Casper Steenholdt
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
MTMichael Tovey
Michael Tovey
TKTobias W. Klausen
Tobias W. Klausen
OTOle Ø. Thomsen
Ole Ø. Thomsen
KBKlaus Bendtzen
Klaus Bendtzen
Several techniques are used to measure infliximab (IFX) and anti-IFX antibodies (Abs) in Crohn's disease. The aim of this study was to compare different assays for this purpose. Fluid-phase radioimmunoassay (RIA), solid-phase enzyme-linked immunosorbent assay (ELISA), reporter gene assay (RGA), and enzyme immunoassay (EIA; anti-IFX Ab only) were assessed. IFX was added to pooled serum from 13 patients with inactive Crohn's disease to yield concentrations of 0, 1, 3, and 9 µg/mL. Anti-IFX Abs were assessed in 6 patients. IFX assessments: RIA and RGA had lower limit of detection than ELISA (0.07 µg/mL and 0.13 versus 0.26). Maximal inaccuracies were 39%, 24%, and 23%. Imprecisions (coefficients of variation) were ≤20% within IFX concentrations between 1 and 9 µg/mL. All assays showed linear correlations (R = 0.97-0.99), but sample concentrations differed by up to 1.55 µg/mL for RIA and RGA, 1.41 µg/mL for ELISA and RIA, and 0.48 µg/mL for ELISA and RGA (P < 0.05). Anti-IFX Ab assessments: RGA gave highly reproducible results (coefficients of variation ≤ 7%) compared with all others (24%-26%). All assays had linear correlations (R = 0.71-0.93), except ELISA versus RGA and EIA. Assays disagreed on anti-IFX Ab titers with mean difference -420 (-1200 to 210) in RGA and EIA, and up to 4500 (-2700 to 11,800) in RIA and RGA. A contributing factor to these discrepancies was inability of ELISA to detect IgG4 anti-IFX Abs. Performances of assays for IFX and anti-IFX Abs are comparable. However, IFX concentrations and anti-IFX Ab titers show systematic differences, and in individual patients, only the same assay should be used. Problems may arise when different assays are used to manage therapies in the same patient.

1 December 2012 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
CSCasper Steenholdt
Casper Steenholdt
MAMagid Al-Khalaf
Magid Al-Khalaf
JBJrn Brynskov
Jrn Brynskov
KBKlaus Bendtzen
Klaus Bendtzen
OTOle. Thomsen
Ole. Thomsen
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth

15 March 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
CSCasper Steenholdt
Casper Steenholdt
AMAkbar Molazahi
Akbar Molazahi
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
JBJørn Brynskov
Jørn Brynskov
OTOle Østergaard Thomsen
Ole Østergaard Thomsen
JSJakob Benedict Seidelin
Jakob Benedict Seidelin
Objective. To investigate duration of remission, including risk factors for relapse and response to retreatment with infliximab (IFX), in patients with Crohn's disease (CD) and ulcerative colitis (UC) who had discontinued IFX while in clinical remission. Methods. Observational, single-center, retrospective study of all patients with a primary response to IFX who discontinued IFX therapy while in steroid-free remission. Relapse was defined as reintroduction of treatment with a biologic, systemic steroid or surgery. Results. Of 219, 53 (24%) CD patients, and 28 of 97 (30%) UC patients discontinued IFX while in clinical steroid-free remission. The proportion of patients in remission declined steadily with 61% of CD patients, and 75% of UC patients being in remission after 1 year. Half the patients maintained remission after median 2 years (680 days (412–948)) and 3.5 years (1334 days (995–1673)), respectively; p = 0.057. Twelve percent with CD and 40% with UC were in remission at the end of follow-up after 10 and 4.5 years, respectively. Longer disease duration was associated with relapse in univariate analysis in CD, OR 1.1 (1.0–1.1), p = 0.022. Of 25, 24 CD patients (96%), and 5 of 7 UC patients (71%) experienced complete clinical remission when retreated with IFX after relapse. Conclusion. While the short-term prognosis seems favorable, the majority of patients who discontinue IFX while in remission relapse over time. The response to retreatment with IFX at relapse seems favorable in this subpopulation.

12 February 2015 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CSCasper Steenholdt
Casper Steenholdt
JBJørn Brynskov
Jørn Brynskov
OTOle Ø. Thomsen
Ole Ø. Thomsen
LMLars K. Munck
Lars K. Munck
JFJan Fallingborg
Jan Fallingborg
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth

1 February 2012 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
CSCasper Steenholdt
Casper Steenholdt
MSMorten Svenson
Morten Svenson
KBKlaus Bendtzen
Klaus Bendtzen
OTOle Østergaard Thomsen
Ole Østergaard Thomsen
JBJørn Brynskov
Jørn Brynskov
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
A 61 year old woman with active luminal Crohn's disease was successfully treated with infliximab induction therapy followed by 5 infusions every 8 weeks. However, symptoms returned in the weeks preceding the 7th and 8th infusions. The 9th infusion was therefore given only 4 weeks after the 8th infusion, but an acute severe anaphylactoid reaction occurred immediately after start of the infusion. Anti-infliximab IgG antibody concentration was high (100 U/ml) prior to the 8th infusion and up to 1 year after infliximab discontinuation (81 U/ml). Anti-infliximab IgE antibodies were not found, and the anti-infliximab antibodies did not cross react with adalimumab. One week after the anaphylactoid reaction to infliximab, adalimumab therapy was initiated. Twelve days after the first adalimumab administration (80 mg), a delayed hypersensitivity reaction occurred. This was likely caused by rapidly generated anti-adalimumab IgG antibodies (45 U/ml), as these antibodies appeared to be specific for adalimumab in that infliximab failed to compete with adalimumab/anti-adalimumab antibody binding ex vivo. In conclusion, immunogenicity to infliximab and adalimumab may be associated with both acute anaphylactoid reactions and delayed hypersensitivity reactions. Reactions may be precipitated by newly induced specific anti-drug antibodies rather than by cross-reactivity of previously generated antibodies.